|
|
|
|
|
|
|
|
|
sponsored by
|
|
|
|
Moving beyond innovation for ADC success
|
| Innovation alone isn’t enough. Antibody-drug conjugates require alignment across dosing, biomarkers and global trial strategy to move programs forward with greater speed and confidence. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Super poop might be the answer to cancer immunotherapy’s inconsistent benefits. Startup Kanvas Biosciences has managed to package dozens of microbes into a single pill it hopes will spread the therapy’s benefits. Endpoints’ Ryan Cross has the details here. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Max Bayer
|
Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and... | |
|
|
|
 |
|
Kanvas Biosciences' imaging technology applied to a mouse colon allows scientists to detect how genes are expressed by different microbes (Courtesy Kanvas) |
|
|
|
by Ryan Cross
|
Scientists trying to understand why cancer immunotherapy works so well for some patients and not others have found a potential answer in one cancer survivor's... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Madrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty... | |
|
|
|
|
|
|
|
|
by Max Gelman
|
Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy's failure in two mid-stage trials. The company... | |
|
|
|
 |
|
Swiss Biotech Day 2026 (Anna Brown for Endpoints News) |
|
|
